ArticleBMC infectious diseases2018
Immune responses in the treatment of drug-sensitive pulmonary tuberculosis with phenylbutyrate and vitamin D
Article in BMC infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01580007 (Clinical Trial of Oral Phenylbutyrate and Vitamin D Adjunctive Therapy in Pulmonary Tuberculosis in Bangladesh), which is not on this map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical Trial of Oral Phenylbutyrate and Vitamin D Adjunctive Therapy in Pulmonary Tuberculosis in Bangladesh: a Pilot Study
Who cites it
34 citing papers in PubMed, 43 citations in OpenAlex.
- Antimicrobial Peptides, Bacteriocins and Mycocins as Natural Antimicrobials: Applications in Food Safety, Agriculture and Healthcare.Antibiotics (Basel, Switzerland) · 2026Review
- Immune endotypes in tuberculosis: Keys to decoding disease complexity.Journal of internal medicine · 2026Review
- Antimycobacterial peptides as natural therapeutics for tuberculosis: mechanisms and structural features.Frontiers in antibiotics · 2026Review
- Immunotherapy for tuberculosis: current strategies and future directions.Military Medical Research · 2025Review
- Bacteriophage immunotherapy with artificial antigen-directed immune labeling against bacterial infection.Science advances · 2025Article
- Progress of anti-tuberculosis drug targets and novel therapeutic strategies.Frontiers in microbiology · 2025Review
- Repurposed Drugs and Plant-Derived Natural Products as Potential Host-Directed Therapeutic Candidates for Tuberculosis.Biomolecules · 2024Review
- Sirtuin inhibitors reduce intracellular growth of M. tuberculosis in human macrophages via modulation of host cell immunity.Scientific reports · 2024Article
- Serotype-Dependent Inhibition ofJournal of microbiology and biotechnology · 2024Article
- Review
- Vitamin D as a Shield against Aging.International journal of molecular sciences · 2023Review
- Antimicrobial peptides´ immune modulation role in intracellular bacterial infection.Frontiers in immunology · 2023Review
- Role of phagocyte extracellular traps duringFrontiers in microbiology · 2023Review
- The gut microbiome: A line of defense against tuberculosis development.Frontiers in cellular and infection microbiology · 2023Review
- Measurement of Autophagy Activity Reveals Time-Dependent, Bacteria-Specific Turnover duringPathogens (Basel, Switzerland) · 2022Article
- Review
- Host-directed therapies in pulmonary tuberculosis: Updates on anti-inflammatory drugs.Frontiers in medicine · 2022Review
- Autophagy-Inflammation Interplay During Infection: Balancing Pathogen Clearance and Host Inflammation.Frontiers in pharmacology · 2022Review
- Biomaterial-based delivery of antimicrobial therapies for the treatment of bacterial infections.Nature reviews. Materials · 2022Article
- Upregulating Human Cathelicidin Antimicrobial Peptide LL-37 Expression May Prevent Severe COVID-19 Inflammatory Responses and Reduce Microthrombosis.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 4 countries.
Funding
Abstract
backgroundWe have previously shown that 8 weeks' treatment with phenylbutyrate (PBA) (500mgx2/day) with or without vitamin D
methodsCytokine concentration was measured in supernatants of peripheral blood mononuclear cells (PBMC) from patients (n = 31/group). Endoplasmic reticulum stress-related genes (GADD34 and XBP1spl) and human beta-defensin-1 (HBD1) gene expression were studied in monocyte-derived-macrophages (MDM) (n = 18/group) from PBMC of patients. Autophagy in MDM (n = 6/group) was evaluated using LC3 expression by confocal microscopy.
resultsA significant decline in the concentration of cytokines/chemokines was noted from week 0 to 8 in the PBA-group [TNF-α (β = - 0.34, 95% CI = - 0.68, - 0.003; p = 0.04), CCL11 (β = - 0.19, 95% CI = - 0.36, - 0.03; p = 0.02) and CCL5 (β = - 0.08, 95% CI = - 0.16, 0.002; p = 0.05)] and vitD
conclusionThe use of PBA and vitD TRIALS REGISTRATION: This trial was retrospectively registered in clinicaltrials.gov, under identifier NCT01580007 .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.